| Report ID | 275263 |
| Drug Identification Number | 02525852 |
| Brand name | BYOOVIZ |
| Common or Proper name | BYOOVIZ |
| Company Name | SAMSUNG BIOEPIS CO., LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | RANIBIZUMAB |
| Strength(s) | 10MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVITREAL |
| Packaging size | Vial + filter needle + injection needle pack & Vial only pack |
| ATC code | S01LA |
| ATC description | OCULAR VASCULAR DISORDER AGENTS |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | |
| Actual start date | 2026-01-01 |
| Estimated end date | 2026-06-30 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2026-01-09 |
| Company comments | The current shortage arises from the delay of contract with new partner followed by the delay in preparing the new supply under the new brand name. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 76, SONGDOGYOYUK-RO, YEONSU-GU INCHEON, INCHEON KOREA, REPUBLIC OF 21987 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2026-01-09 | French | Compare |
| v4 | 2026-01-09 | French | Compare |
| v3 | 2026-01-09 | English | Compare |
| v2 | 2026-01-06 | French | Compare |
| v1 | 2026-01-06 | English | Compare |
Showing 1 to 5 of 5